A Single, Interpretable Vocal Biomarker for Enriching Antipsychotic Clinical Trials.

Alex S Cohen¹, Brian Kirkpatrick², Mark Opler³, Kazunori Tatsumi⁴, Seema Bhat⁵, Laxminarayan Bhat⁵

¹Department of Psychology, Louisiana State University, Baton Rouge, Louisiana; Center for Computation and Technology, Louisiana State University, Baton Rouge, Louisiana; Quantic Innovations, Inc., Benton, Arkansas. Electronic address: acohen@lsu.edu.

²Quantic Innovations, Inc., Benton, Arkansas; Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

³Clario, Inc., Philadelphia, Pennsylvania; The PANSS Institute, New York, New York.

⁴Clario, Inc., Philadelphia, Pennsylvania.

⁵Reviva Pharmaceuticals Inc., Cupertino, California.

PubMed DOI

Abstract

BACKGROUND: Speech latency, an objective measure of verbal response time, is sensitive to cognitive, social, and motivational factors and can be measured using recordings of psychiatric interviews. Emerging evidence suggests that it can be used to enrich participants in antidepressant clinical trials, resulting in nearly double the drug-placebo effect at half the sample size. Here, we evaluated wh…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.